Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Trial record 1 of 1 for:    TRC105 Progressive or Recurrent Metastatic Breast Cancer
Previous Study | Return to List | Next Study

Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer (TRC105)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2014 by Tracon Pharmaceuticals Inc..
Recruitment status was  Active, not recruiting
Roswell Park Cancer Institute
United States Department of Defense
Information provided by (Responsible Party):
Tracon Pharmaceuticals Inc. Identifier:
First received: March 25, 2011
Last updated: August 27, 2014
Last verified: May 2014
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2014
  Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)